Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

ABSTRACT: Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecular remission status Hazard ratios (HR) were estimated for patients registered to CML study IV who were divided in a learning and a validation sample. The minimum HR for MMR was found at 2.5 years with 0.28 (compared to patients without remission). In the validation sample, a significant advantage for progression-free survival (PFS) for patients in MMR could be detected (p-value 0.007). The optimal time to predict PFS in patients with MMR could be validated in an independent sa

SUBMITTER: Saussele S 

PROVIDER: S-EPMC5940636 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature